See, reach, treat: Ultrasound-triggered image-guided drug delivery

Therapeutic Delivery

Volumn 2, Issue 7, 2011, Pages 919-934

  Sanches, Pedro Gomes ^a   Grüll, Holger ^a,b   Steinbach, Oliver C ^b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DOXORUBICIN; DRUG CARRIER; GADOTERIDOL; INTERCELLULAR ADHESION MOLECULE 1; LIPOSOME; PERFLUTREN; PLASMID DNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SONOVUE; SURVIVIN;

COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HYPERTHERMIC THERAPY; IMAGE GUIDED DRUG DELIVERY; IN VITRO STUDY; IN VIVO STUDY; MICROBUBBLE; MONITORING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; TEMPERATURE SENSITIVITY;

EID: 79961205685     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.63     Document Type: Review

References (151)

1. Vosburgh KG, Jolesz FA. The concept of image-guided therapy. Acad. Radiol. 10(2), 176-179 (2003). (Pubitemid 36150971)
2. Haigron P, Dillenseger JL, Luo L, Coatrieux JL. Image-guided therapy: evolution and breakthrough. IEEE Eng. Med. Biol. Mag. 29(1), 100-104 (2010).
3. Solorio L, Patel RB, Wu H, Krupka T, Exner A. Advances in image guided intratumoral drug delivery techniques. Therapeutic Delivery 1(2), 307-322 (2010).
4. Goodwin SC, Spies JB. Uterine fibroid embolization. N. Engl. J. Med. 361(7), 690-697 (2009).
5. Rivard MJ, Venselaar JL, Beaulieu L. The evolution of brachytherapy treatment planning. Med. Phys. 36(6), 2136-2153 (2009).
6. Shen SH, Fennessy F, Mcdannold N, Jolesz F, Tempany C. Image-guided thermal therapy of uterine fibroids. Semin. Ultrasound CT MR 30(2), 91-104 (2009).
7. Moonen CT. Spatio-temporal control of gene expression and cancer treatment using magnetic resonance imaging-guided focused ultrasound. Clin. Cancer Res. 13(12), 3482-3489 (2007). (Pubitemid 46955107)
8. Hindley J, Gedroyc WM, Regan L et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am. J. Roentgenol. 183(6), 1713-1719 (2004). (Pubitemid 44210545)
9. Hokland SL, Pedersen M, Salomir R, Quesson B, Stodkilde-Jorgensen H, Moonen CTW: MRI-guided focused ultrasound: methodology and applications. IEEE Trans. Med. Imaging 25(6), 723-731 (2006). (Pubitemid 44143889)
10. Hynynen K, McDannold N. MRI guided and monitored focused ultrasound thermal ablation methods: a review of progress. Intl J. Hyperthermia 20(7), 725-737 (2004). (Pubitemid 39496853)
11. Moonen CT, Quesson B, Salomir R et al. Thermal therapies in interventional MR imaging. Focused ultrasound. Neuroimaging Clin. N. Am. 11(4), 737-747 (2001). (Pubitemid 34132343)
12. Schmitz AC, Gianfelice D, Daniel BL, Mali WP, Van Den Bosch MA. Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions. Eur. Radiol. 18(7), 1431-1441 (2008).
13. Kennedy JE: High-intensity focused ultrasound in the treatment of solid tumours. Nat. Rev. Cancer 5(4), 321-327 (2005). (Pubitemid 40488637)
14. Enholm JK, Kohler MO, Quesson B, Mougenot C, Moonen CT, Sokka SD. Improved volumetric MR-HIFU ablation by robust binary feedback control. IEEE Trans. Biomed. Eng. 57(1), 103-113 (2010).
15. Kohler MO, Mougenot C, Quesson B et al. Volumetric HIFU ablation under 3D guidance of rapid MRI thermometry. Med. Phys. 36(8), 3521-3535 (2009).
16. Palussiere J, Salomir R, Le Bail B et al. Feasibility of MR-guided focused ultrasound with real-time temperature mapping and continuous sonication for ablation of VX2 carcinoma in rabbit thigh. Magn. Reson. Med. 49(1), 89-98 (2003). (Pubitemid 36042337)
17. Goldberg SN, Ahmed M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J. Clin. Gastroenterol. 35(5 Suppl. 2), S115-S129 (2002). (Pubitemid 35278649)
18. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J. Clin. Oncol. 25(8), 978-986 (2007). (Pubitemid 350002864)
19. Ter Haar G. Therapeutic applications of ultrasound. Prog. Biophys. Mol. Biol. 93(1-3), 111-129 (2007).
20. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv. Drug Deliv. Rev. 60(10), 1193-1208 (2008).
21. Deckers R, Moonen CTW. Ultrasound triggered, image guided, local drug delivery. J. Control. Release 148(1), 25-33 (2010).
22. Deckers R, Rome C, Moonen CT. The role of ultrasound and magnetic resonance in local drug delivery. J. Magn. Reson. Imaging 27(2), 400-409 (2008). (Pubitemid 351214046)
23. Pan H, Zhou Y, Izadnegahdar O, Cui J, Deng CX. Study of sonoporation dynamics affected by ultrasound duty cycle. Ultrasound Med. Biol. 31(6), 849-856 (2005). (Pubitemid 40776083)
24. Van Wamel A, Kooiman K, Harteveld M et al. Vibrating microbubbles poking individual cells: drug transfer into cells via sonoporation. J. Control. Release 112(2), 149-155 (2006).
25. Zhou Y, Cui J, Deng CX. Dynamics of sonoporation correlated with acoustic cavitation activities. Biophys. J. 94(7), L51-L53 (2008).
26. Zhou Y, Kumon RE, Cui J, Deng CX. The size of sonoporation pores on the cell membrane. Ultrasound Med. Biol. 35(10), 1756-1760 (2009).
27. Marmottant P, Hilgenfeldt S. Controlled vesicle deformation and lysis by single oscillating bubbles. Nature 423(6936), 153-156 (2003). (Pubitemid 36569534)
28. Deng CX. Targeted drug delivery across the blood-brain-barrier using ultrasound technique. Therapeutic Delivery 1(6), 819-848 (2010).
29. Frenkel V, Li KC. Potential role of pulsed-high intensity focused ultrasound in gene therapy. Future Oncol. 2(1), 111-119 (2006).
30. Mayer CR, Bekeredjian R. Ultrasonic gene and drug delivery to the cardiovascular system. Adv. Drug Deliv. Rev. 60(10), 1177-1192 (2008).
31. Suzuki R, Oda Y, Utoguchi N, Maruyama K. Progress in the development of ultrasound-mediated gene delivery systems utilizing nano- and microbubbles. J. Control. Release 149(1), 36-41 (2011).
32. Qin SP, Caskey CF, Ferrara KW. Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineering. Physics Med. Biol. 54(6), R27-R57 (2009).
33. Weinstein JN, Magin RL, Yatvin MB, Zaharko DS. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 204(4389), 188-191 (1979). (Pubitemid 9194553)
34. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202(4374), 1290-1293 (1978). (Pubitemid 9154441)
35. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 53(3), 285-305 (2001). (Pubitemid 34024911)
36. Falk MH, Issels RD. Hyperthermia in oncology. Int. J. Hyperthermia 17(1), 1-18 (2001). (Pubitemid 32058478)
37. Hokland SL, Pedersen M, Salomir R, Quesson B, Stodkilde-Jorgensen H, Moonen CT. MRI-guided focused ultrasound: methodology and applications. IEEE Trans. Med. Imaging 25(6), 723-731 (2006). (Pubitemid 44143889)
38. Hynynen K, Freund WR, Cline HE et al. A clinical, noninvasive, MR imaging-monitored ultrasound surgery method. Radiographics 16(1), 185-195 (1996). (Pubitemid 126448421)
39. Quesson B, De Zwart JA, Moonen CT. Magnetic resonance temperature imaging for guidance of thermotherapy. J. Magn. Reson. Imaging 12(4), 525-533 (2000).
40. Staruch R, Chopra R, Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int. J. Hyperthermia 27(2), 156-171 (2011).
41. Negussie AH, Yarmolenko PS, Partanen A et al. Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int. J. Hyperthermia 27(2), 140-155 (2011).
42. De Smet M, Heijman E, Langereis S, Hijnen NM, Grull H. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study. J. Control. Release 150(1), 102-110 (2011).
43. De Smet M, Langereis S, Van Den Bosch S, Grull H. Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J. Control. Rel. 143(1), 120-127 (2009).
44. Issels RD, Lindner LH, Verweij J et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised Phase 3 multicentre study. Lancet Oncol. 11(6), 561-570 (2010).
45. Van Der Zee J, Gonzalez GD. The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int. J. Hyperthermia 18(1), 1-12 (2002). (Pubitemid 34092370)
46. Van Der Zee J, Hulshof MC. Lessons learned from hyperthermia. Int. J. Radiat. Oncol. Biol. Phys. 57(2), 596-597; author reply 599-600 (2003).
47. Van Der Zee J, Van Rhoon GC. Cervical cancer: radiotherapy and hyperthermia. Int. J. Hyperthermia 22(3), 229-234 (2006).
48. Jones EL, Oleson JR, Prosnitz LR et al. Randomized trial of hyperthermia and radiation for superficial tumors. J. Clin. Oncol. 23(13), 3079-3085 (2005). (Pubitemid 46224131)
49. Overgaard J, Gonzalez Gonzalez D, Hulshof MC et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int. J. Hyperthermia 12(1), 3-20 (1996). (Pubitemid 26096961)
50. Van Der Zee J. Heating the patient: a promising approach? Ann. Oncol. 13(8), 1173-1184 (2002).
51. Issels RD. Hyperthermia adds to chemotherapy. Eur. J. Cancer 44(17), 2546-2554 (2008).
52. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 60(5), 1197-1201 (2000). (Pubitemid 30151982)
53. Lindner LH, Eichhorn ME, Eibl H et al. Novel temperature-sensitive liposomes with prolonged circulation time. Clin. Cancer Res. 10(6), 2168-2178 (2004). (Pubitemid 38375579)
54. Lindner LH, Hossann M. Factors affecting drug release from liposomes. Curr. Opin. Drug Discov. Devel. 13(1), 111-123 (2010).
55. Zwart JD, Salomir R, Vimeux FC, Klaveness J, Moonen CTW. On the feasibility of local drug delivery using themo-sensitive liposomes and MR-guided focused ultrasound. Proc. ISMRM 8, 43 (2000).
56. Ponce AM, Viglianti BL, Yu DH et al. Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects. J. Natl Cancer Instit. 99(1), 53-63 (2007).
57. Viglianti BL, Abraham SA, Macfall JR, Bally MB, Dewhirst MW. In vivo monitoring of real-time tissue pharmacokinetics of liposome-drug concentration using MRI. Radiology 225, 647-648 (2002).
58. Viglianti BL, Abraham SA, Michelich CR et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Mag. Res. Med. 51(6), 1153-1162 (2004). (Pubitemid 38797000)
59. Viglianti BL, Ponce AM, Michelich CR et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Mag. Res. Med. 56(5), 1011-1018 (2006). (Pubitemid 44691343)
60. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv. Drug Deliv. Rev. 60(10), 1153-1166 (2008).
61. Schneider M. Molecular imaging and ultrasound-assisted drug delivery. J. Endourol. 22(4), 795-801 (2008). (Pubitemid 351550759)
62. Hancock HA, Smith LH, Cuesta J et al. Investigations into pulsed high-intensity focused ultrasound-enhanced delivery: preliminary evidence for a novel mechanism. Ultrasound Med. Biol. 35(10), 1722-1736 (2009).
63. Kollmann C. New sonographic techniques for harmonic imaging - underlying physical principles. Eur. J. Radiol. 64(2), 164-172 (2007). (Pubitemid 47588756)
64. Bohmer MR, Klibanov AL, Tiemann K, Hall CS, Gruell H, Steinbach OC. Ultrasound triggered image-guided drug delivery. Eur. J. Radiol. 70(2), 242-253 (2009).
65. Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Ann. Rev. Biomed. Eng. 9, 415-447 (2007). (Pubitemid 350246663)
66. Schmidt B, Souza I, Van Beek A, Bohmer M. Adhesion and ultrasound-induced delivery from monodisperse microbubbles in a parallel plate flow cell. J. Control. Release 131(1), 19-26 (2008).
67. Rödel J, Straube E, Lungershausen W, Hartmann M, Groh A. Secretion of cytokines by human synoviocytes during in vitro infection with Chlamydia trachomatis. J. Rheumatol. 25(11), 2161-2168 (1998). (Pubitemid 28505863)
68. Shi WT, Bohmer M, Van Wamel A et al. Ultrasound therapy with drug loaded microcapsules. 2007 IEEE Ultrasonics Symposium 773-776 (2007).
69. Borden MA, Caskey CF, Little E, Gillies RJ, Ferrara KW. DNA and polylysine adsorption and multilayer construction onto cationic lipid-coated microbubbles. Langmuir 23(18), 9401-9408 (2007). (Pubitemid 47383531)
70. Lentacker I, De Geest BG, Vandenbroucke RE et al. Ultrasound-responsive polymer-coated microbubbles that bind and protect DNA. Langmuir 22(17), 7273-7278 (2006). (Pubitemid 44366426)
71. Lentacker I, De Smedt SC, Demeester J, Sanders NN. Microbubbles which bind and protect DNA against nucleases. J. Control. Release 116(2), E73-E75 (2006).
72. Vandenbroucke RE, Lentacker I, Demeester J, De Smedt SC, Sanders NN. Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles. J. Control. Release 126(3), 265-273 (2008).
73. Lentacker I, Geers B, Demeester J, De Smedt SC, Sanders NN. Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved. Mol. Ther. 18(1), 101-108 (2010).
74. Geers B, Lentacker I, Sanders NN, Demeester J, Meairs S, De Smedt SC. Self-assembled liposome-loaded microbubbles: the missing link for safe and efficient ultrasound triggered drug-delivery. J. Control. Release (2011) (In press).
75. Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim. Biophys. Acta 1778(3), 794-809 (2008). (Pubitemid 351317803)
76. Walsh DA. Pathophysiological mechanisms of angiogenesis. Adv. Clin. Chem. 44, 187-221 (2007).
77. Villanueva FS, Jankowski RJ, Klibanov S et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation 98(1), 1-5 (1998). (Pubitemid 28312070)
78. Ellegala DB, Leong-Poi H, Carpenter JE et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to a(v)b3. Circulation 108(3), 336-341 (2003). (Pubitemid 36899026)
79. Deshpande N, Needles A, Willmann JK. Molecular ultrasound imaging: current status and future directions. Clin. Radiol. 65(7), 567-581 (2010).
80. Leong-Poi H, Christiansen J, Heppner P et al. Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation 111(24), 3248-3254 (2005). (Pubitemid 40874997)
81. Willmann JK, Paulmurugan R, Chen K et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246(2), 508-518 (2008).
82. Takalkar AM, Klibanov AL, Rychak JJ, Lindner JR, Ley K. Binding and detachment dynamics of microbubbles targeted to P-selectin under controlled shear flow. J. Control. Release 96(3), 473-482 (2004). (Pubitemid 38553925)
83. Schneider M, Pochon S, Tardy I et al. Angiogenic molecular imaging with KDR-targeted microbubbles. Contrast Media Mol. Imaging 2, 274-304 (2007).
84. Della Martina A, Allemann E, Bettinger T et al. Grafting of abciximab to a microbubble-based ultrasound contrast agent for targeting to platelets expressing GP IIb/ IIIa - characterization and in vitro testing. Eur. J. Pharm. Biopharm. 68(3), 555-564 (2008). (Pubitemid 351318198)
85. Pochon S, Tardy I, Bussat P et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest. Radiol. 45(2), 89-95 (2010).
86. Fujii H, Li SH, Wu J et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur. Heart J. (2011) (Epub ahead of print).
87. Carson AR, Mctiernan CF, Lavery L et al. Gene therapy of carcinoma using ultrasound-targeted microbubble destruction. Ultrasound Med. Biol. 37(3), 393-402 (2011).
88. Ghanem A, Steingen C, Brenig F et al. Focused ultrasound-induced stimulation of microbubbles augments site-targeted engraftment of mesenchymal stem cells after acute myocardial infarction. J. Mol. Cell. Cardiol. 47(3), 411-418 (2009).
89. Seip R, Chin CT, Hall Cs, Raju BI, Ghanem A, Tiemann K. Targeted ultrasound-mediated delivery of nanoparticles: on the development of a new HIFU-based therapy and imaging device. IEEE Transactions on Biomedical Engineering 57(1), 61-70 (2009).
90. Ter Haar GR. Ultrasonic contrast agents: safety considerations reviewed. Eur. J. Radiol. 41(3), 217-221 (2002). (Pubitemid 34171564)
91. Ay T, Havaux X, Van Camp G et al. Destruction of contrast microbubbles by ultrasound: effects on myocardial function, coronary perfusion pressure, and microvascular integrity. Circulation 104(4), 461-466 (2001). (Pubitemid 32678278)
92. Van Camp G, Ay T, Pasquet A et al. Quantification of myocardial blood flow and assessment of its transmural distribution with real-time power modulation myocardial contrast echocardiography. J. Am. Soc. Echocardiogr. 16(3), 263-270 (2003). (Pubitemid 36397621)
93. Vanoverschelde JL, Vancrayenest D, Ay T, Peltier M, Pasquet A. Assessment of myocardial blood flow using myocardial contrast echocardiography. Am. J. Cardiol. 90(10A), 59J-64J (2002). (Pubitemid 35346869)
94. Miller DL. WFUMB safety symposium on echo-contrast agents: in vitro bioeffects. Ultrasound Med. Biol. 33(2), 197-204 (2007). (Pubitemid 46240592)
95. Miller DL, Averkiou MA, Brayman AA et al. Bioeffects considerations for diagnostic ultrasound contrast agents. J. Ultrasound Med. 27(4), 611-632; quiz 633-616 (2008). (Pubitemid 351489681)
96. Tsutsui JM, Xie F, Porter RT. The use of microbubbles to target drug delivery. Cardiovasc. Ultrasound 2, 23 (2004).
97. Pecot CV, Calin GA, Coleman RL, Lopez- Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11(1), 59-67 (2011).
98. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discovery Today 11(1-2), 67-73 (2006). (Pubitemid 43227854)
99. Chen S, Ding JH, Bekeredjian R et al. Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc. Natl Acad. Sci. USA 103(22), 8469-8474 (2006). (Pubitemid 43838479)
100. Check E. A tragic setback. Nature 420(6912), 116-118 (2002). (Pubitemid 35340095)
101. Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: an update on delivery. Curr. Opin. Mol. Ther. 10(2), 158-167 (2008). (Pubitemid 351498878)
102. Su H, Huang Y, Takagawa J et al. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther. 13(21), 1495-1502 (2006). (Pubitemid 44567147)
103. Grimm D, Pandey K, Kay MA. Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol. 392, 381-405 (2005). (Pubitemid 40092527)
104. Grimm D. Small silencing RNAs: state-of-the-art. Adv. Drug Deliv. Rev. 61(9), 672-703 (2009).
105. Andino LM, Takeda M, Kasahara H, Jakymiw A, Byrne BJ, Lewin AS. AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes. J. Gene Med. 10(2), 132-142 (2008). (Pubitemid 351267155)
106. Li Hl, Zheng XZ, Wang HP, Li F, Wu Y, Du LF. Ultrasound-targeted microbubble destruction enhances AAV-mediated gene transfection in human RPE cells in vitro and rat retina in vivo. Gene Ther. 16(9), 1146-1153 (2009).
107. Muller OJ, Schinkel S, Kleinschmidt JA, Katus HA, Bekeredjian R. Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats. Gene Ther. 15(23), 1558-1565 (2008).
108. Luten J, Van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for pDNA delivery. J. Control. Release 126(2), 97-110 (2008).
109. Oberle V, De Jong G, Drayer JI, Hoekstra D. Efficient transfer of chromosome-based DNA constructs into mammalian cells. Biochim Biophys. Acta 1676(3), 223-230 (2004). (Pubitemid 38231047)
110. Cejka D, Losert D, Wacheck V. Short interfering RNA (siRNA): tool or therapeutic? Clin. Sci. (Lond).110(1), 47-58 (2006). (Pubitemid 43059044)
111. Chen SH, Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations. Eur. J. Clin. Invest. 41(2), 221-232 (2011).
112. Phalon C, Rao DD, Nemunaitis J. Potential use of RNA interference in cancer therapy. Exp. Rev. Mol. Med. 12, E26 (2010).
113. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/ DNA complexes. J. Control. Release 91(1-2), 173-181 (2003). (Pubitemid 37288888)
114. Godbey WT, Barry MA, Saggau P, Wu KK, Mikos AG. Poly(ethylenimine)- mediated transfection: a new paradigm for gene delivery. J. Biomed. Mater. Res. 51(3), 321-328 (2000). (Pubitemid 30452134)
115. Kim Y, Tewari M, Pajerowski JD et al. Polymersome delivery of siRNA and antisense oligonucleotides. J. Control. Release 134(2), 132-140 (2009).
116. Nishikawa M, Takakura Y, Hashida M. Theoretical considerations involving the pharmacokinetics of pDNA. Adv. Drug Del. Rev. 57(5), 675-688 (2005). (Pubitemid 40332596)
117. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2(12), 711-719 (2006). (Pubitemid 44764213)
118. Skinner SA, Tutton PJ, O'Brien PE. Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 50(8), 2411-2417 (1990). (Pubitemid 20134503)
119. Decuzzi P, Causa F, Ferrari M, Netti PA. The effective dispersion of nanovectors within the tumor microvasculature. Ann. Biomed. Eng. 34(4), 633-641 (2006).
120. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001). (Pubitemid 32476118)
121. Soutschek J, Akinc A, Bramlage B et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014), 173-178 (2004). (Pubitemid 39545841)
122. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387-6392 (1986). (Pubitemid 17221789)
123. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21(5), 797-802 (2010).
124. Dobrovolskaia MA, Aggarwal P, Hall JB, Mcneil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008).
125. Brinkmann V, Reichard U, Goosmann C et al. Neutrophil extracellular traps kill bacteria. Science 303(5663), 1532-1535 (2004). (Pubitemid 38314426)
126. Bartneck M, Keul HA, Zwadlo-Klarwasser G, Groll J. Phagocytosis independent extracellular nanoparticle clearance by human immune cells. Nano Lett. 10(1), 59-63 (2010).
127. Judge AD, Sood V, Shaw JR, Fang D, Mcclintock K, Maclachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23(4), 457-462 (2005). (Pubitemid 41724921)
128. Robbins M, Judge A, Maclachlan I. siRNA and innate immunity. Oligonucleotides 19(2), 89-102 (2009).
129. Sakamoto JH, Van De Ven AL, Godin B et al. Enabling individualized therapy through nanotechnology. Pharmacol. Res. 62(2), 57-89 (2010).
130. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Rel. 129(2), 107-116 (2008).
131. Decuzzi P, Ferrari M. The receptor-mediated endocytosis of nonspherical particles. Biophys. J. 94(10), 3790-3797 (2008).
132. Hong H, Zhang Y, Cai W. In vivo imaging of RNA interference. J. Nucl. Med. 51(2), 169-172 (2010).
133. Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28(8), 1565-1571 (2007). (Pubitemid 46039833)
134. Ferrara KW. Driving delivery vehicles with ultrasound. Adv. Drug Del. Rev. 60(10), 1097-1102 (2008).
135. Chumakova OV, Liopo AV, Andreev VG et al. Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett. 261(2), 215-225 (2008).
136. Moreira JN, Santos A, Moura V, Pedroso De Lima MC, Simoes S. Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing. J. Nanosci. Nanotechnol. 8(5), 2187-2204 (2008).
137. Lu QL, Bou-Gharios G, Partridge TA: Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. 10(2), 131-142 (2003). (Pubitemid 36582585)
138. Huber PE, Pfisterer P. In vitro and in vivo transfection of pDNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther. 7(17), 1516-1525 (2000).
139. Vorhies JS, Nemunaitis J. Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Exp. Rev. Anticancer Ther. 7(3), 373-382 (2007). (Pubitemid 46488341)
140. Iwanaga K, Tominaga K, Yamamoto K et al. Local delivery system of cytotoxic agents to tumors by focused sonoporation. Cancer Gene Ther. 14(4), 354-363 (2007). (Pubitemid 46425785)
141. Larkin JO, Casey GD, Tangney M et al. Effective tumor treatment using optimized ultrasound-mediated delivery of bleomycin. Ultrasound Med. Biol. 34(3), 406-413 (2008). (Pubitemid 351625449)
142. Staples BJ, Pitt WG, Roeder BL, Husseini GA, Rajeev D, Schaalje GB. Distribution of doxorubicin in rats undergoing ultrasonic drug delivery. J. Pharm. Sci. 99(7), 3122-3131 (2010).
143. Chen ZY, Liang K, Xie MX, Wang XF, Lu Q, Zhang J. Induced apoptosis with ultrasound-mediated microbubble destruction and shRNA targeting survivin in transplanted tumors. Advances in Therapy 26(1), 99-106 (2009).
144. Suzuki J, Ogawa M, Takayama K et al. Ultrasound-microbubble-mediated intercellular adhesion molecule-1 small interfering ribonucleic acid transfection attenuates neointimal formation after arterial injury in mice. J. Am. Coll. Cardiol. 55(9), 904-913 (2010).
145. Xenariou S, Griesenbach U, Liang HD et al. Use of ultrasound to enhance nonviral lung gene transfer in vivo. Gene Ther. 14(9), 768-774 (2007). (Pubitemid 46585658)
146. Hosseinkhani H, Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. Enhanced suppression of tumor growth using a combination of NK4 pDNA-PEG engrafted cationized dextran complex and ultrasound irradiation. Cancer Gene Ther. 13(5), 479-489 (2006).
147. Hauff P, Seemann S, Reszka R et al. Evaluation of gas-filled microparticles and sonoporation as gene delivery system: feasibility study in rodent tumor models. Radiology 236(2), 572-578 (2005). (Pubitemid 41023442)
148. Chen Z, Liang K, Xie M, Wang X, Lu Q, Zhang J. Novel ultrasound-targeted microbubble destruction mediated short hairpin RNA plasmid transfection targeting survivin inhibits gene expression and induces apoptosis of HeLa cells. Mol. Biol. Rep. 36(8), 2059-2067 (2009).
149. Chen ZY, Liang K, Qiu RX. Targeted gene delivery in tumor xenografts by the combination of ultrasound-targeted microbubble destruction and polyethylenimine to inhibit survivin gene expression and induce apoptosis. J. Exp. Clin. Cancer Res. 29, 152 (2010).
150. Russ V, Wagner E. Cell and tissue targeting of nucleic acids for cancer gene therapy. Pharm. Res. 24(6), 1047-1057 (2007). (Pubitemid 46798888)
151. Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291), 1067-1070 (2011).